Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.

Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.

Insurers and pharmaceutical companies urge CMS to allow health plans to use their pharmacy and therapeutics committees to design formularies for individual and small group plans.

Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large number of the industry's best customers do reduce their medication use in the donut hole-and if a customer is lost to the donut hole, they may be lost for good.